Read by QxMD icon Read

Post chemotherapy cognitive impairment

Omar F Khan, Ellen Cusano, Soundouss Raissouni, Mica Pabia, Johanna Haeseker, Nicholas Bosma, Jenny J Ko, Haocheng Li, Aalok Kumar, Michael M Vickers, Patricia A Tang
BACKGROUND: Cognitive impairment is commonly reported in patients receiving chemotherapy, but the acuity of onset is not known. This study utilized the psychomotor vigilance test (PVT) and trail-making test B (TMT-B) to assess cognitive impairment immediately post-chemotherapy. METHODS: Patients aged 18-80 years receiving first-line intravenous chemotherapy for any stage of breast or colorectal cancer were eligible. Patient symptoms, peripheral neuropathy and Stanford Sleepiness Scale were assessed...
February 14, 2019: BMC Cancer
Nathalie Zandbergen, Belle H de Rooij, M Caroline Vos, Johanna M A Pijnenborg, Dorry Boll, Roy F P M Kruitwagen, Lonneke V van de Poll-Franse, Nicole P M Ezendam
BACKGROUND: While many cancer survivors experience persistent impairments in health-related quality of life (HRQoL) for extended periods of time, others recover soon after treatment. The aim of this research is to assess changes in health-related quality of life in endometrial and ovarian cancer survivors during two years post initial treatment, and to assess clinical and sociodemographic characteristics associated with those changes. METHODS: This prospective population-based cohort study includes longitudinal data of endometrial (N = 221) and ovarian (N = 174) cancer survivors diagnosed between 2011 and 2014...
January 30, 2019: Acta Oncologica
Margaret F Bedillion, Emily B Ansell, Gwendolyn A Thomas
OBJECTIVES: Breast cancer survivors report significant cognitive impairments post treatment, particularly following chemotherapy. Depression may also occur post treatment and may partially mediate the effects of cancer treatment on cognition. Additionally, physical activity has been shown to mitigate treatment effects on cognition and depression. This study examined the role of depression in mediating the effects of cancer treatment on cognitive function (perceived cognitive impairment, PCI; perceived cognitive ability, PCA) in breast cancer survivors and explored the role of physical activity in moderating these effects...
January 16, 2019: Breast: Official Journal of the European Society of Mastology
David P Jarmolowicz, Rachel Gehringer, Shea M Lemley, Michael J Sofis, Sam Kaplan, Michael A Johnson
Chemotherapy related cognitive impairment (CTRC; "chemobrain") is a syndrome that is associated with the impairment of various aspects of cognition, including executive function, processing speed, and multitasking. The role of neurotransmitter release in the expression of cognitive impairments is not well known. In this work we employed a newly developed behavioral paradigm to measure attentional shifting, a fundamental component of executive function, in rats treated with 5-fluorouracil (5-FU), a commonly used cancer chemotherapy agent...
January 7, 2019: Behavioural Brain Research
Yujie Zhang, Yu-Chen Chen, Lanyue Hu, Jia You, Wei Gu, Qian Li, Huiyou Chen, Cunnan Mao, Xindao Yin
Previous studies have demonstrated that cognitive impairment is associated with neurophysiological changes in lung cancer following chemotherapy. This study aimed to investigate the intrinsic functional connectivity (FC) pattern within the default mode network (DMN) and its associations with cognitive impairment in patients with lung cancer revealed by resting-state functional magnetic resonance imaging (fMRI). Resting-state fMRI scans were acquired from 21 post-chemotherapy and 27 non-chemotherapy lung cancer patients and 30 healthy controls...
January 7, 2019: Brain Imaging and Behavior
Noemí Cerulla, Àngels Arcusa, José-Blas Navarro, Nuria de la Osa, Maite Garolera, Cristina Enero, Glòria Chico, Luís Fernández-Morales
Chemotherapy-Related Cognitive Impairment (CRCI) can be an adverse effect in women treated for breast cancer. Some longitudinal studies reported deficits in attention, memory, and executive function following treatment, but other studies did not find cognitive changes. It is known that practice effects (PE) on repeated assessments with cognitive tests contribute to the discrepancies in these results, but its influence on scores has not been systematically explored. The present study examines the impact of PE on retest scores in a group of women with breast cancer treated with chemotherapy and evaluated longitudinally...
November 26, 2018: Journal of Clinical and Experimental Neuropsychology
Kimberly D van der Willik, Vincent Koppelmans, Michael Hauptmann, Annette Compter, M Arfan Ikram, Sanne B Schagen
BACKGROUND: Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global cognitive performance. METHODS: One hundred sixty-six breast cancer survivors who received post-surgical radiotherapy and six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy on average 20 years before enrollment were compared with 1344 cancer-free women from a population-based sample (50-80 years old)...
November 15, 2018: Breast Cancer Research: BCR
Naghmehossadat Eshghi, Linda Garland, Gagandeep Choudhary, Charles C Hsu, Anna Eshghi, James Han, Russell J Hamilton, Elizabeth Krupinski, Phillip Hsin Kuo
Objective: Chemotherapy followed by prophylactic cranial irradiation (PCI) is associated with increased survival in patients with small cell lung cancer (SCLC) but is associated with fatigue and cognitive impairment. This retrospective study evaluated regional differences in fluorodeoxyglucose (18 F-FDG) uptake of the brain before and after PCI. The null hypothesis was that direct toxic effects on the brain from PCI and chemotherapy are symmetric, thus asymmetric deviations may reflect functional changes due to therapy...
August 3, 2018: Journal of Nuclear Medicine Technology
Estherina Trachtenberg, Tatiana Mashiach, Rachel Ben Hayun, Tamar Tadmor, Tali Fisher, Judith Aharon-Peretz, Eldad J Dann
Cancer-related cognitive impairment (CRCI) is commonly reported post-chemotherapy in adults with solid tumours. Hodgkin lymphoma (HL) mostly affects young adults. Data regarding CRCI in HL survivors (HLS) are scarce. The current study aimed to objectively assess CRCI incidence and characteristics in HLS. HLS, who completed first-line (chemotherapy ± radiation) therapy and remained in complete remission for 6 months to 5 years from therapy end, were evaluated. Age- and education-matched healthy individuals served as controls (n = 14)...
September 2018: British Journal of Haematology
Simone Darling, Cinzia Rachele De Luca, Vicki Anderson, Maria McCarthy, Stephen Hearps, Marc Seal
BACKGROUND: Approximately 50% of survivors of childhood acute lymphoblastic leukemia (ALL) demonstrate cognitive impairments. However, the trajectory of change and contributing neuropathology is unclear, limiting our ability to tailor intervention content and timing. This study aimed to explore information processing abilities and brain morphology early post-treatment for pediatric ALL. PROCEDURE: Twenty-one children at the end of ALL treatment and 18 controls underwent neuropsychological assessment...
July 3, 2018: Developmental Neurorehabilitation
Jennifer N Vega, Julie Dumas, Paul A Newhouse
OBJECTIVE: Cancer-related cognitive impairment (CRCI) is commonly reported following the administration of cancer treatment. Current longitudinal studies, primarily in women with breast cancer, suggest that up to 35% to 60% of patients exhibit persistent CRCI (pCRCI) following completion of chemotherapy. Complaints of subjective cognitive decline (SCD) are also commonly reported by women during and following the menopause transition in noncancer patients. Although the majority of evidence for cognitive difficulties in cancer patients and survivors is attributed to chemotherapy, there is growing evidence to suggest that menopausal status can also influence cognitive function in cancer patients...
September 2018: Psycho-oncology
Eyal Asor, Dorit Ben-Shachar
Chemotherapy-induced cognitive changes is a major burden on a substantial number of cancer survivors. The mechanism of this sequel is unknown. In this study, we followed long-term effects of early in life mithramycin (MTR) treatment on behaviour and on the normal course of alterations of gene expression in brain. Between post-natal days (PND) 7 and 10, male rats were divided into 2 groups, 1 receiving MTR (0.1 mg/kg s.c. per day) and the other receiving saline. At PND11, frontal cortex tissue samples were dissected from 4 rats from each group...
October 2018: Clinical and Experimental Pharmacology & Physiology
Mingmei Li, Karen Caeyenberghs
In addition to the burden of a life-threatening diagnosis, cancer patients are struggling with adverse side-effects from cancer treatment. Chemotherapy has been linked to an array of cognitive impairments and alterations in brain structure and function ("chemobrain"). In this review, we summarized the existing evidence that evaluate the changes in cognitive functioning and brain with chemotherapy, as assessed using structural and functional MRI-based techniques in a longitudinal design. This review followed the latest PRISMA guidelines using Embase, Medline, PsychINFO, Scopus, and Web of Science databases with date restrictions from 2012 to 2017...
September 2018: Neuroscience and Biobehavioral Reviews
Ashley M Henneghan, Oxana Palesh, Michelle Harrison, Shelli R Kesler
INTRODUCTION: The purpose of this study is to explore 13 cytokine predictors of chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors (BCS) 6 months to 10 years after chemotherapy completion using a multivariate, non-parametric approach. METHODS: Cross sectional data collection included completion of a survey, cognitive testing, and non-fasting blood from 66 participants. Data were analyzed using random forest regression to identify the most significant predictors for each of the cognitive test scores...
July 15, 2018: Journal of Neuroimmunology
Ashley M Henneghan, Patricia Carter, Alexa Stuifbergan, Brennan Parmelee, Shelli Kesler
OBJECTIVE: Links have been made between aspects of sleep quality and cognitive function in breast cancer survivors (BCS), but findings are heterogeneous. The objective of this study is to examine relationships between specific sleep quality components (latency, duration, efficiency, daytime sleepiness, sleep disturbance, use of sleep aids) and cognitive impairment (performance and perceived), and determine which sleep quality components are the most significant contributors to cognitive impairments in BCS 6 months to 10 years post chemotherapy...
August 2018: Psycho-oncology
Thomas M Field, Mimi Shin, Chase S Stucky, Joseph Loomis, Michael A Johnson
Post-chemotherapy cognitive impairment, also known as 'chemobrain,' is a neurological condition in which cognitive function is impaired as a result of cancer chemotherapy treatment. In this work, we used fast-scan cyclic voltammetry (FSCV) to measure electrically evoked dopamine release and uptake in whole brain preparations from zebrafish that have been treated with carboplatin, an agent associated with chemobrain. We administered carboplatin by addition to the fish's tank water or their food. One week of treatment with 100 μM carboplatin in the water was needed to significantly impair dopamine release (∼40 % of control); however, only one day of treatment through the zebrafish's food was needed to cause a similar impairment...
May 22, 2018: Chemphyschem: a European Journal of Chemical Physics and Physical Chemistry
Wei Liu, Yin Ting Cheung, Heather M Conklin, Lisa M Jacola, DeoKumar Srivastava, Vikki G Nolan, Hongmei Zhang, James G Gurney, I-Chan Huang, Leslie L Robison, Ching-Hon Pui, Melissa M Hudson, Kevin R Krull
PURPOSE: The purpose of this study was to determine the evolution of neurocognitive problems from therapy completion to long-term follow-up in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. METHODS: We evaluated whether attention problems observed at therapy completion evolve into long-term executive dysfunction in 158 survivors treated on a single institution protocol. Treatment data (high-dose intravenous methotrexate exposure [serum concentration] and triple intrathecal chemotherapy injections) were collected...
June 2018: Journal of Cancer Survivorship: Research and Practice
Hye-Sang Park, Chang-Ju Kim, Hyo-Bum Kwak, Mi-Hyun No, Jun-Won Heo, Tae-Woon Kim
Although chemotherapy increases the survival rate of patients with various cancers, such treatment can induce acute or long-term cognitive dysfunction a phenomenon known as post-chemotherapy cognitive impairment (PCCI) or "chemobrain." Exercise is known to positively affect brain function. Thus, the present study aimed to determine whether symptoms of chemobrain and disruptions in the neuroplasticity and functioning of hippocampal mitochondria can be prevented or relieved by exercise. Wistar rats were separated into the following groups: control, control plus exercise, chemobrain, and chemobrain plus exercise...
May 1, 2018: Neuropharmacology
M Simó, A Gurtubay-Antolin, L Vaquero, J Bruna, A Rodríguez-Fornells
No previous event-related potentials (ERPs) study has explored the error-related negativity (ERN) - an ERP component indexing performance monitoring - associated to cancer and chemotherapy-induced cognitive impairment in a lung cancer population. The aim of this study was to examine differences in performance monitoring in a small-cell lung cancer group (SCLC, C +) 1-month following chemotherapy and two control groups: a non-small cell lung cancer patient group (NSCLC, C -) prior to chemotherapy and a healthy control group (HC)...
2018: NeuroImage: Clinical
Terence Ng, Sreemanee Raaj Dorajoo, Yin Ting Cheung, Yick Ching Lam, Hui Ling Yeo, Maung Shwe, Yan Xiang Gan, Koon Mian Foo, Wei-Jen Kiley Loh, Si-Lin Koo, Amit Jain, Guek Eng Lee, Rebecca Dent, Yoon Sim Yap, Raymond Ng, Alexandre Chan
OBJECTIVES: Currently, there are no studies that have established the self-perceived cognitive trajectories experienced by breast cancer patients (BCPs) post-chemotherapy. Therefore, we characterized the long-term trajectory of self-perceived cognitive function among Asian early-stage BCPs using the minimal clinically important difference of a subjective measure of cognitive function. METHODS: Early-stage BCPs who received chemotherapy were recruited and assessed at 4 time points: Before chemotherapy initiation (T1), 6 weeks post-chemotherapy initiation (T2), 12 weeks post-chemotherapy initiation (T3), and 15-months post-chemotherapy initiation (T4)...
April 2018: Psycho-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"